Discover 3,059 paid clinical trials in Cambridge, Massachusetts. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,059
Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss
Location: Boston MA, Allentown PA, Bethesda MD, Oklahoma City OK
Sponsor: Skylark Bio Inc.
Sex: All
Age: 0 - 7
Code: NCT07627971
Phase 1, Phase 2, Recruiting
ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty
for
Corneal Transplant Failure
Location: Boston MA, Towson MD, Durham NC, Ann Arbor MI,
Sponsor: Massachusetts Eye and Ear Infirmary
Sex: All
Age: 18+
Code: NCT06753916
Phase 2, Recruiting
Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema
for
Cystoid Macular Edema
Location: Boston MA
Sponsor: Massachusetts Eye and Ear Infirmary
Sex: All
Age: 18 - 70+
Code: NCT04225611
Phase 1, Phase 2, Recruiting
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
for
Glaucoma
Location: Boston MA, Baltimore MD, Buffalo NY, Toronto,
Sponsor: University of Pennsylvania
Sex: All
Age: 18+
Code: NCT05924477
Recruiting
ctDNA in Cutaneous Squamous Cell Carcinoma
for
Cutaneous Squamous Cell Carcinoma
Location: Boston MA
Sponsor: Massachusetts Eye and Ear Infirmary
Sex: All
Age: 18+
Code: NCT06875609
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Improving Clinical Efficiency by Reducing Scheduled Follow-ups Using Cochlear America's Population Mean Mapping Strategy
for
Deafness, Cochlear Hearing Loss
Location: Boston MA
Sponsor: Massachusetts Eye and Ear Infirmary
Sex: All
Age: 18 - 70+
Code: NCT06960616
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
for
Triple Negative Locally Advanced Non-resectable Breast Cancer,
Location: Boston MA, Toronto, Columbus OH, Nashville TN,
Sponsor: Marengo Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06827613
Phase 1, Phase 2, Recruiting
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas